Related Experiment Video

Updated: Aug 24, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Fluvastatin reduces cardiac mortality in patients with coronary heart disease

Christie M Ballantyne1, Günter Riegger, Nicholas Moore

  • 1Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, Texas 77030, USA. cmb@bcm.tmc.edu

Cardiovascular Drugs and Therapy
|April 30, 2004
PubMed

Insights

Fluvastatin significantly reduces cardiac and all-cause mortality in patients with coronary heart disease (CHD). This meta-analysis supports fluvastatin use for lowering major adverse cardiac events (MACE) in at-risk individuals.

Area of Science:

  • Cardiology
  • Pharmacology
  • Evidence-based Medicine

Background:

  • Coronary heart disease (CHD) poses a significant risk for cardiac and all-cause mortality.
  • Statins are widely used to manage dyslipidemia and reduce cardiovascular events.
  • The specific role of fluvastatin in reducing mortality in CHD patients requires comprehensive evaluation.

Purpose of the Study:

  • To evaluate the effectiveness of fluvastatin (40-80 mg) in reducing cardiac and all-cause mortality in patients with CHD.
  • To assess the impact of fluvastatin on major adverse cardiac events (MACE) in this population.

Main Methods:

  • A meta-analysis of clinical trials investigating fluvastatin in CHD patients was conducted.
  • Pooled analysis of four studies (n=3525) on an intent-to-treat basis.
  • Key endpoints included incidence and time to MACE (cardiac death, MI, revascularization), noncardiac death, and all-cause death. Lipid parameters were also analyzed.

Main Results:

  • Fluvastatin significantly prolonged time to cardiac death and cardiac death or nonfatal MI.
  • Reduced risk of MACE, cardiac death, cardiac death or MI, all-cause death, and all-cause death or MI.
  • Significantly lowered total cholesterol and LDL cholesterol; well-tolerated with no rhabdomyolysis.

Conclusions:

  • Fluvastatin demonstrates clear benefits in reducing cardiac and all-cause mortality in CHD patients.
  • Supports fluvastatin's use for decreasing MACE incidence in diverse at-risk patient groups.
  • Highlights fluvastatin's efficacy and safety profile in managing cardiovascular risk.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...